CN101180065A - 用于预防和治疗2型糖尿病的包含知母皂苷a-ⅲ的组合物 - Google Patents
用于预防和治疗2型糖尿病的包含知母皂苷a-ⅲ的组合物 Download PDFInfo
- Publication number
- CN101180065A CN101180065A CNA2006800174863A CN200680017486A CN101180065A CN 101180065 A CN101180065 A CN 101180065A CN A2006800174863 A CNA2006800174863 A CN A2006800174863A CN 200680017486 A CN200680017486 A CN 200680017486A CN 101180065 A CN101180065 A CN 101180065A
- Authority
- CN
- China
- Prior art keywords
- iii
- type
- timosaponin
- diabetes
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 230000002265 prevention Effects 0.000 title abstract description 11
- MMTWXUQMLQGAPC-YXOKLLKRSA-N Timosaponin A-III Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MMTWXUQMLQGAPC-YXOKLLKRSA-N 0.000 title abstract description 5
- MMTWXUQMLQGAPC-XWIAVXRASA-N timosaponin A-III Natural products C[C@@H]1CC[C@@]2(OC1)O[C@@H]3C[C@H]4[C@H]5CC[C@@H]6C[C@H](CC[C@]6(C)[C@H]5CC[C@]4(C)[C@@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O)[C@H]7O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O MMTWXUQMLQGAPC-XWIAVXRASA-N 0.000 title abstract description 5
- 235000013402 health food Nutrition 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 18
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 32
- 239000008280 blood Substances 0.000 description 32
- 206010012601 diabetes mellitus Diseases 0.000 description 30
- 239000003814 drug Substances 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 16
- 229960001052 streptozocin Drugs 0.000 description 15
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 14
- 230000001939 inductive effect Effects 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010023379 Ketoacidosis Diseases 0.000 description 4
- 208000007976 Ketosis Diseases 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- -1 alloxan anion Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 102000005861 leptin receptors Human genes 0.000 description 3
- 108010019813 leptin receptors Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229930193981 timosaponin Natural products 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 2
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 2
- 108091052347 Glucose transporter family Proteins 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 238000013295 T2DM animal model Methods 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011697 diabetes animal model Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013925 ferrous lactate Nutrition 0.000 description 2
- 229940037907 ferrous lactate Drugs 0.000 description 2
- 239000004225 ferrous lactate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical group [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229940089784 niacinamide 20 mg Drugs 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及用于预防或治疗2型糖尿病的包含知母皂苷A-III的组合物,和特别地,其涉及用于预防或治疗2型糖尿病、包含作为活性成分的知母皂苷A-III的组合物,这可由知母皂苷A-III在预防或治疗2型糖尿病的效果优异而在预防1型糖尿病上效果较差的发现(与已知的知识相反)来支持。
Description
技术领域
本发明涉及用于预防或治疗2型糖尿病的组合物,所述组合物包含知母皂苷A-III,特别地涉及用于预防或治疗2型糖尿病的组合物,所述组合物包含作为活成分的知母皂苷A-III,这可由知母皂苷A-III在预防和治疗2型糖尿病中具有优异的效果而在预防或治疗1型糖尿病中效果不佳的发现(与已知的知识相反)支持。
背景技术
根据国立卫生研究院(NIH),大约有1,570位遭受2型糖尿病(肥胖相关性疾病的一种)的患者[证据报导:clinical guideline on theidentification,evaluation,and treatment of overweight andobesity in adults,1999,NIH]。
此外,WHO预期2025年糖尿病患者的人数将达到大约3亿人。特别地,遭受2型糖尿病(其中胰岛素缺乏控制血糖水平的功能)的患者总计大约为美国人口的5.9%[A.S.Wagman等人,CurrentPharmaceutical Design,7,417,2001]。
糖尿病是涉及碳氢化合物的代谢作用的疾病并且显示高血糖水平的症状。该疾病分为1型糖尿病(胰岛素依赖型糖尿病;大约为总患者的10%)和2型糖尿病(非胰岛素依赖性糖尿病;大约为总患者的90%)[B.Set,Clin Therapeu.,25,1895,2003;S.N.Davis,JDiabetes Complications.,18,367,2004]。因为由于遗传或病毒侵害从而导致胰腺中β细胞的破坏而造成的胰腺损害,1型糖尿病患者具有很低的分泌胰岛素的能力或没有分泌胰岛素的能力。此外,这些患者显示非常高的血糖血平,该高血糖水平可能进一步发展至酮病和酮症酸中毒(ketoasidosis)的症状。1型糖尿病主要发生在儿童期,必需通过施用胰岛素来控制血糖水平。相反地,2型糖尿病通常在成人中发现并且因遗传、肥胖症、压力、激素分泌异常和药物的使用而发生。患者可分泌但以非常常低的量分泌胰岛素或因为不利活性激素的分泌增加而致不平衡。2型糖尿病据报导源于对恰当的胰岛素分泌的阻塞、肝中内源性葡萄糖的产生增加或由于周围组织中较低的葡萄糖利用而造成的胰岛素抗性。尽管该疾病也可发展至高血糖水平,但患者不会象1型糖尿病患者那样对酮病和酮症酸中毒敏感。在1型糖尿病的情况下,可通过膳食控制、锻炼和胰岛素药物治疗降低血糖水平。然而,2型糖尿病要求额外地施用降血糖水平药物。
根据作用机制可将降血糖药物分成三类。磺酰脲类或基于氯茴苯酸的药物是第一类,其刺激胰腺中的β细胞以提高胰岛素分泌。第二类是胰岛素敏化剂例如基于双胍或噻唑烷二酮类的药物。阿卡玻糖或米格列醇包括在第三类中,其抑制糖类的降解和在肠中降低糖类的吸收。优选降血糖水平药物应当在进餐后快速抑制血糖水平的过度增加,并且也失去活性而不导致低血糖水平。此外,其应当改善糖尿病伴随的异常代谢。在该方面,前述药物并非完全适宜,因此必需发展口服施用以适当地治疗在世界范围内正在增加的糖尿病的稳定的降血糖水平药物。
在1型糖尿病动物模型中,存在使用四氧嘧啶或链脲霉素的药物诱导的模型和通过培育糖尿病诱导的动物数代产生的天然诱导的模型例如NOD(非肥胖糖尿病)小鼠和BB(bio breeding)大鼠。相反地,基因工程产生的模型广泛地用于2型糖尿病动物模型,代表性实例是db/db小鼠(因来普汀受体的缺陷产生的糖尿病模型)、ob/ob小鼠(因来普汀受体的缺陷导致的肥胖症模型)、zucker(肥胖性糖尿病模型)大鼠、OLETF(The Otsuka Long-Evans Tokushima fatty;肥胖和葡萄糖抗性糖尿病模型)大鼠、KK(肥胖糖尿病模型)小鼠、KK-Ay(肥胖糖尿病、高胰岛素血症模型)小鼠[S.Makino等人,Exp Anim.,29,1,1980;A.F.Nakhooda等人,Diabetes,26,100,1977;M.Nakamura等人,Diabetol,3,121,1967;K.Kawano等人,Diabetes,41,1422,1992;D.A.Rees等人,Diabetic Medicine,22,359,2005]。因此,理解各动物模型(1型、2型)的性质和选择最适当的模型是非常重要的。
相关的现有技术
N.Nakashima等人报导了伪知母皂苷(pseudotimosaponin)A-III、原知母皂苷(prototimosaponin)A-III、知母皂苷A-III在大鼠中降低血糖水平的效果,在所述大鼠中,糖尿病由四氧嘧啶和链脲霉素诱导,所述药物是用于实验性糖尿病模型中的代表性药物[N.Nakashima等人,J.Nat.Prod.第56卷,345,1994]。除此以外,知母皂苷A-III据报导具有抑制血小板聚集[A.Niwa等人,YakugakuZasshi 108(6),555,1988]和舒张血管[G.Wang等人,Life Sci.71,1081,2002]的活性。
四氧嘧啶和链脲霉素用作诱导1型糖尿病的代表性药物,因为其通过葡萄糖转运蛋白(GLUT-2)的表达进入胰腺中的β细胞,诱导DNA的破坏或NAD+的耗尽,从而导致胰腺中的β细胞的编程性细胞死亡。[K.Bloch等人,Diabetes Metab Res Rev 21,253,2005;D.A.Rees等人,Diabetic Medicine,22,359,2005;J.Kawada等人,YakugakuZasshi,112,773,1992;V.M.F.Rastelli等人,Inflamm Res.,54,173,2005;R.K.Cuman等人,Inflamm Res.50,460,2001;参考图1]。
四氧嘧啶(5,5-二羟基-2,4,6(1H,3H,5H)-嘧啶三酮)是尿酸的氧化产物或嘧啶衍生物。四氧嘧啶阴离子通过细胞色素P-450介导的自由基反应破坏胰腺中的β细胞[K.Bloch等人,Diabetes Metab ResRev 21,253,2005;Yakugaku Zasshi,112,773,1992]。然而,已报导四氧嘧啶具有毒性且导致动物的高死亡率。I.F.Federiuk等人试图发现通过改变四氧嘧啶的给药途径或剂量来使四氧嘧啶诱导的糖尿病模型中的死亡率减少至最低的最佳方法。结果,高剂量的四氧嘧啶(200mg/kg)的腹膜内施用减少死亡率10%,且诱导超过70%的1型糖尿病[I.F.Federiuk,Compara Med,54,252,2004]。
链脲霉素(2-脱氧-2-(3-甲基-3-亚硝基脲基)-D-吡喃葡萄糖)(葡萄糖衍生物)基于强烷基化作用进入β细胞并产生超氧自由基,从而导致对所述β细胞的氧化破坏。超氧自由基的产生由XOD(黄嘌呤氧化酶)的间接激活(该激活由当抑制线粒体产生ATP时产生的细胞中高浓度的ADP导致)或由XOD(黄嘌呤氧化酶)的直接激活[D.A.Rees等人,Diabetic Medicine,22,359,2005;Yakugaku Zasshi,112,773,1992]诱导。
尽管已报导通过使用链脲霉素来诱导2型糖尿病,但这些报导的大多数公开了需要与诱导2型糖尿病的药物施用例如额外药物例如***[S.J.Giddings等人,Diabetes,34,235,1985]、尼克酰胺[S.Ozyazgan等人,Pharmacol.,74,119,2005]或至少1至2周的高脂饮食[R.de Souza Santos等人,Clin Chim Acta.,2005,Epubahead of print;M.J.Reed等人,Metabolism.,49,1390,2000;F.Zhang等人,Exp Anim.,52,401,2003]的施用一起进行的额外测量。即,由单独的链脲霉素(无论剂量或给药途径)诱导的病症是1型糖尿病,这似乎是毫无疑问的。该链脲霉素诱导的糖尿病动物模型应当区别于新生期链脲霉素(在下文中称为‘n-链脲霉素’)在两天龄大鼠中诱导的糖尿病模型[I.Degirmenci等人,J EthnopharmacoL,97,555,2005;D.N.Umrani等人,Clin Exp Hypertens.,25,221,2003]。N-链脲霉素-诱导的糖尿病大鼠模型是广泛使用的2型糖尿病模型,事实上,所述报导也明确地描述了在成年大鼠中链脲霉素诱导的糖尿病模型是1型模型而在新生大鼠中n-链脲霉素-诱导的糖尿病模型是2型模型[B.M.Kim.,Diabetol.,44,2192,2001;V.M.F.Rastelli等人,Inflamm Res.,54,173,2005;R.K.Cuman等人,Inflamm Res.50,460,2001;U.A.Shinde等人,J Cell Mol Med.,7,322,2003;U.A.Shindea等人,J Trace Elem Med Biol.,18,23,2004]。
总之,N.Nakashima等人报导的[N.Nakashima等人,J.Nat.Prod,第56卷,345,1994]知母皂苷A-III在降低血水平中的效果只适用于1型糖尿病模型,这与在此处所述的2型糖尿病中降低血糖水平的活性无关。此外,N.Nakashima等人只公开了降低血糖水平的比较活性,而根本没有描述降低血糖水平的绝对效果。因此,N.Nakachima等人未能显示,基于知母皂苷A-III具有比此处所述的原知母皂苷A-III或伪知母皂苷A-III更弱的活性的事实,知母皂苷A-III在2型糖尿病模型中在降低血糖水平中具有优异的效果。
因此本发明的目的在于提供知母皂苷A-III在预防或治疗2型糖尿病中的新用途。
发明详述
本发明涉及用于预防或治疗2型糖尿病的组合物,其包含作为活性成分的知母皂苷。
此外,本发明涉及包含作为活性成分的知母皂苷A-III、对于2型糖尿病是有效的保健食品。
在下文中提供了本发明的详细描述。
本发明由以下发现来支持,所述发现是,与已知的知识相反,知母皂苷A-III在预防或治疗2型糖尿病中效果优异而在预防或治疗1型糖尿病中效果较差。
在本发明中,从知母分离出式(I)的知母皂苷A-III(3-O-β-D-吡喃葡萄糖基-(1→2)-β-D-吡喃半乳糖基)菝葜皂苷元。
用于从知母根茎(知母)分离知母皂苷A-III的方法包括:
(a)在含醇水溶液中获得知母根茎的萃取物(下文中称为‘知母’)并用三蒸水回收萃取物;
(b)用相同量的己烷使回收的萃取物分层,然后除去上层;
(c)用相同量的二氯甲烷洗涤下面的水层,用相同量的乙酸乙酯分层,然后分离乙酸乙酯层;和
(d)使用硅胶柱层析对分离的乙酸乙酯层进行分级分离,通过使用二噁烷水溶液的重结晶分离和获得知母皂苷。
本发明确定了,与已知的知识相反,知母皂苷A-III在预防或治疗2型糖尿病中的效果非常优异而在预防或治疗1型糖尿病中的效果较差。
因此,本发明涉及用于预防或治疗2型糖尿病、包含作为活性成分的知母皂苷A-III的组合物。
此处的组合物(当接受临床检测时)可通过口服或胃肠外例如通过静脉内、皮下、腹膜和局部给药进行施用,和可以药物或保健食品的形式使用。
可将此处的组合物配制成片剂、丸剂、乳剂或液体剂型、气溶胶、药片、含锭、水或油混悬剂、制剂、粉剂、颗粒剂、乳剂、硬或软胶囊、糖浆剂或酏剂。片剂或胶囊制剂可包含粘合剂例如乳糖、蔗糖、山梨糖醇、甘露醇、淀粉、支链淀粉、纤维素或明胶;赋形剂例如磷酸二钙;崩解剂例如玉米淀粉或甘薯淀粉;润滑剂例如硬脂酸镁、硬脂酸钙、硬脂酰醇富马酸钠或聚乙二醇蜡。胶囊制剂还可包含液体载体。此外,可胃肠外例如皮下、静脉内、肌内或胸部(pectoral)注射施用此处的组合物。可通过将此处的组合物与稳定剂或缓冲剂在水中混合,然后配制成安瓿或小瓶的单剂型来生产胃肠外制剂。
合适的载体、赋形剂和稀释剂实例是铝盐、苯氧基乙醇、水、生理盐水溶液、乳糖、葡萄糖、山梨糖醇、甘露醇、硅酸钙、纤维素、甲基纤维素、维晶纤维素、聚乙烯吡咯烷酮、羟苯甲酯、羟苯丙酯、滑石、硬脂酸镁和矿物油。
此外,此处组合物的任何制剂还可包含充填剂、抗集结剂、润滑剂、湿润剂、调味品、悬浮剂或防腐剂。
同时,可通过考虑各种信息例如活性成分的吸收水平、失活率、***率或患者的年龄、性别、身体健康状况等来确定此处的活性成分的合适的剂量水平。在优选实施方案中,成人的剂量水平是每天0.1-15g。
此处的组合物可配制为食物或药物,和可按照前述的日剂量每天服用1次或2两次。
如此处所用,‘保健食品’是指以胶囊、粉剂或悬浮剂的形式存在的食物,通过在不同食物例如饮料、茶、调味品、树胶、点心中加入此处的活性成分从而提供想要的效果(同时与药物不同,在服用后长时间无任何副作用)来制备所述保健食品。
附图概述
图1显示由四氧嘧啶和链脲霉素产生的β细胞的破坏过程。
图2是显示知母乙酸乙酯级分(AA-EA)和其亚级分(EA-I~EA-V)在db/db小鼠模型中降低血糖水平的效果的图。
图3是显示知母皂苷A-III在db/db小鼠模型中降低血糖水平的效果的图。
图4是显示知母皂苷A-III在KK-Ay小鼠模型中降低血糖水平的效果的图。
图5是显示知母皂苷A-III在链脲霉素诱导的糖尿病大鼠模型中降低血糖水平的效果的图。
实施例
通过下列实施例更明确地描述本发明。此处的实施例只是用于举例说明本发明的,而不已任何方式限定本发明。
预备实施例1:来自知母的活性EA级分的制备
将3kg的知母浸没在20L 50%的乙醇中进行4小时,进行2次。在80℃下,在搅拌的情况下进行该过程以获得有效的萃取。4小时后,将固体沉淀,用漏斗和吸水棉除去最终的漂浮材料。用旋转蒸发器蒸馏滤液,称取由此获得的萃取物的重量。将100g萃取物回收在500mL三蒸水中,重复该过程。将获得的萃取物与相同量的n-己烷(Jinchemicals pharmaceutical Co.Ltd.,Korea)混合,并在分液漏斗中搅拌。24小时后,除去上面的己烷层,重复该过程2或3次。
以与上述方法相同的方法用相同量的二氯甲烷(Jin chemicalspharmaceutical Co.Ltd.,Korea,在下文中称为“MC”)洗涤剩下的水层3或4次。将剩下的水层与相同量的乙酸乙酯(Jin chemicalspharmaceutical Co.Ltd.,Korea,在下文中称为“EA”)混合,并置于分液漏斗中。24小时后,除去上面的EA层。通过用EA进行2或3次分级分离获得想要的知母EA级分(AA-EA),然后在减少的压力下对其进行浓缩。将其雾化并在-20℃下贮存以待使用。
预备实施例2:知母EA级分的亚分级分离
将290g知母EA级分(AA-EA)接受使用硅胶柱层析(170-230目,3kg)的连续分级分离。通过分别使用15L的下列溶剂:EA(15L)、EA∶MeOH=20∶1(20L)、EA∶MeOH∶水=20∶2∶0.1(20L)、EA∶MeOH∶水=10∶2∶0.2(20L)获得5种不同的级分。所述级分按照该顺序称为EA-I、EA-II、EA-III、EA-IV和EA-V。在减少的压力下浓缩各级分,雾化所述级分并在-20℃下贮存以待使用。
预备实施例3:活性成分的分离和结构表征
将40mL 70%的二噁烷水溶液加入1g知母EA亚级分(EA-V),通过水浴和超声处理将其完全溶解。将溶解的EA-V级分在室温下放置24小时,从而提供白色针状材料。通过过滤白色针状材料制备的材料称作化合物I(Rf 0.38,90% MeOH,在5% ethanolic H2SO4喷雾后炭化,RP-18 F254s,MERCK)。
使用H1-NMR,C13-NMR和ESI-MS对分离的化合物I进行结构表征,并确定所述化合物为以前报导的知母皂苷A-III[S.Saito等人,Chem.Pharm.Bull.2342.1994]。此外,标准化的产物可商购获得(SKF 7862,WAKO pure chemical industries.LTD.),并确定为与使用HPLC获得的材料相同的材料。
实施例1:在db/db小鼠模型中降低血糖水平的效果
将8-9周龄的db/db雄性小鼠(C57BL/Ks-db/db)用于本实验。由美国的Jackson实验室发展的C57BL/Ks-db/db小鼠在出生后4-5周开始肥胖并且经历血糖水平的升高,因为下丘脑中来普汀受体的缺乏而通过异常的信号传输***诱导肥胖相关性糖尿病。因为该性质,其用作用于分析和发现糖尿病、肥胖症和其并发症的机制或用于筛选降血糖水平的药物的代表性2型糖尿病动物模型[D.A.Rees等人,Diabetic Medicine,22,359,2005;G.H.Lee等人,Nature,379,632,1996;S.C.Chua等人,Science,271,994,1996;J.K.Naggert等人,Mamm Genome.,6,131,1995]。
每天下午,给实验组施用检测药物,分别使阴性对照组和阳性对照组接受腹膜内或口服施用0.5%羧甲基纤维素(CMC)溶液和溶解在0.5%羧甲基纤维素(CMC)溶液中的罗西格列酮。以3-4天的间隔在下午正好在计划的施用时间之前,通过切割尾静脉来测量血糖水平。以2天的间隔正好在施用之前称取小鼠和饲料的重量。在施用后,称重和测量,进行10天,从采集的血液中分离血清,并测量各种生物化学参数以分析肝脏或肾脏的脂质和功能。
图2显示在施用300mg/kg预备实施例1中制备的知母EA级分(AA-EA)和在预备实施例2中制备的300mg/kg亚级分(EA-I、EA-II、EA-III、EA-IV、EA-V)后降低血糖水平的效果。
结果,确定了与知母EA级分(AA-EA)相比,EA-V显示更优的活性。此外,由于所述活性与阳性对照相等,所以将该级分接受活性成分的筛选。
图3显示在分别以100mg/kg、200mg/kg和3000mg/kg的剂量施用预备实施例3中制备的知母皂苷A-III后降低血糖水平的效果。该图显示了在200mg/kg的剂量上与阳性对照相同的效果,在300mg/kg的剂量上显示了降低血糖水平的甚至更优的效果,这确定了知母皂苷A-III是EA-V级分中的主要活性成分。
实施例2:知母皂苷A-III在KK-Ay小鼠中降低血糖的效果
将9-10周龄的KK-Ay雄性小鼠(C57BL/Ks)用于本实验。通过将肥胖基因导入KK小鼠产生KK-Ay小鼠,所述KK小鼠源于KaskabeSaitamihyun Japan并由Takeda Pharmaceutical IndustryCorporation发展用于遗传研究。其用作在早期显示肥胖症和高胰岛素血症(由于高血糖水平导致的)的2型糖尿病模型[M.Okazaki等人,Exp Anim.,51,191,2002;J.Suto等人,Eur J Endocrinol.,139,654,1998]。
每天下午使阴性对照组和实验组分别接受0.5%羧甲基纤维素(CMC)溶液和溶解在0.5%羧甲基纤维素(CMC)中的受试药物的口服施用。以3-4天的间隔在下午正好在计划的施用时间之前,通过切割尾静脉来测量血糖水平。以2天的间隔正好在施用之前称取小鼠和饲料的重量。在施用后,称重和测量,进行8天,从采集的血液中分离血清,测量各种生物化学参数以分析肝脏或肾脏的脂质和功能。
图4显示分别以100mg/kg和200mg/kg的剂量施用预备实施例3中制备的知母皂苷A-III后降低血糖水平的效果。在200mg/kg的剂量上确定了强降血糖效果。
实施例3:知母皂苷A-III在链脲霉素诱导的糖尿病大鼠中降低血糖水平的效果
用溶解在50mM柠檬酸缓冲液(pH 4.5)中的链脲霉素(STZ:40mg/kg)对7周龄的wistar雄性大鼠(体重:180-200g)腹膜内施用一次。在STZ施用后5天,选择显示稳定的高于400mg/dl的血糖水平的大鼠并将其用于实验。
每天下午给实验组施用受试药物,使阴性对照组和阳性对照组分别接受0.5%羧甲基纤维素(CMC)溶液和溶解在0.5%羧甲基纤维素(CMC)溶液中的格列本脲的口服施用,进行8天。以3-4天的间隔在下午正好在计划的施用时间之前,通过切割尾静脉来测量血糖水平。以2天的间隔正好在施用之前称取小鼠和饲料的重量。
图5显示在预备实施例3中制备的知母皂苷A-III在链脲霉素诱导的糖尿病大鼠即1型糖尿病模型中降低血糖水平的效果。与N.Nakashima等人[N.Nakashima等人,J.Nat.Prod,第56卷,345,1994]的报导相反,知母皂苷A-III(150mg/kg)不确定具有统计学意义上显著的降低血糖水平的效果。
基于前述实施例1-3的结果,本发明者确定知母皂苷A-III在2型糖尿病中具有很强的和选择性降血糖水平的效果。
实施例4:知母皂苷A-III在ICR小鼠中的毒性检测
为进行毒性研究,在知母皂苷A-III的重复剂量(1g)的情况下,选择16-小时-禁食的4-5周龄的ICR小鼠(每组5只小鼠)作为受试者。口服施用1g溶解在0.5%羧甲基纤维素(CMC)的知母皂苷A-III,进行5天。没有死亡的受试者也没有异常发现例如对内脏器官的损伤。
配制实施例1:粉剂和胶囊剂的制备
将100mg知母皂苷A-III与14.8mg乳糖、3mg微晶纤维素和0.2mg硬脂酸镁混合。通过使用合适的装置将所述混合物填充入5号明胶胶囊中。
配制实施例2:软膏的制备
如下面所示通过使用知母皂苷A-III制备软膏:
活性成分5g、鲸蜡醇十六醇酯20g、鲸蜡醇40g、硬脂醇40g、十四烷酸异丙酯80g、失水山梨醇单硬脂酸酯20g、聚山梨醇酯60g、对羟基苯甲酸丙酯1g、对羟基苯甲酸甲酯1g和合适量的蒸馏水以及磷酸。
实施例3:注射液的制备
如下所示通过使用知母皂苷A-III制备注射液:
活性成分100mg、甘露醇180mg、磷酸氢二钠25mg、注射用蒸馏水2974mg。
制备实施例4:保健食品的制备
如下所示,通过使用0.3g知母皂苷A-III、基于日剂量的粉剂化的维生素E、乳酸亚铁、氧化锌、尼克酰胺、维生素A、维生素B1和维生素B2制备保健食品。健康食品的内容物如下(基于日剂量):
活性成分 300mg
人参萃取物 100mg
绿茶萃取物 100mg
维生素C 100mg
粉剂化维生素E 120mg
乳酸亚铁 2mg
氧化锌 2mg
尼克酰胺 20mg
维生素A 5mg
维生素B1 2mg
维生素B2 2mg
玉米淀粉 200mg
硬脂酸镁 20mg
如上所述,本发明在用于预防或治疗2型糖尿病的药物或健康食品中非常有用,因为与已知的知识相反,知母皂苷A-II在预防或治疗2型糖尿病中的效果非常优异而在预防或治疗1型糖尿病中效果较差。
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050077988A KR101235115B1 (ko) | 2005-08-24 | 2005-08-24 | 티모사포닌 a-ⅲ을 함유하는 제2형 당뇨병 예방 및치료용 조성물 |
KR1020050077988 | 2005-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101180065A true CN101180065A (zh) | 2008-05-14 |
Family
ID=37771810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800174863A Pending CN101180065A (zh) | 2005-08-24 | 2006-08-24 | 用于预防和治疗2型糖尿病的包含知母皂苷a-ⅲ的组合物 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR101235115B1 (zh) |
CN (1) | CN101180065A (zh) |
WO (1) | WO2007024108A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105616435A (zh) * | 2016-02-20 | 2016-06-01 | 通化华夏药业有限责任公司 | 知母皂苷ai作为二肽基肽酶ⅳ抑制剂及制备方法和用途 |
CN110025717A (zh) * | 2019-05-20 | 2019-07-19 | 上海中医药大学 | 知母皂苷酶解转化物在制备抑制皮肤浅表真菌药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040063290A (ko) * | 2003-01-06 | 2004-07-14 | 에스케이케미칼주식회사 | 지모 추출물의 제조방법과 그 추출물을 함유한 당뇨병관련 질환 치료용 의약 조성물 |
KR100661397B1 (ko) * | 2004-01-02 | 2006-12-27 | 한국 한의학 연구원 | 티모사포닌 에이-ⅲ를 유효성분으로 하는 성장호르몬분비촉진용 조성물 |
-
2005
- 2005-08-24 KR KR1020050077988A patent/KR101235115B1/ko not_active IP Right Cessation
-
2006
- 2006-08-24 WO PCT/KR2006/003332 patent/WO2007024108A1/en active Application Filing
- 2006-08-24 CN CNA2006800174863A patent/CN101180065A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105616435A (zh) * | 2016-02-20 | 2016-06-01 | 通化华夏药业有限责任公司 | 知母皂苷ai作为二肽基肽酶ⅳ抑制剂及制备方法和用途 |
CN110025717A (zh) * | 2019-05-20 | 2019-07-19 | 上海中医药大学 | 知母皂苷酶解转化物在制备抑制皮肤浅表真菌药物中的应用 |
CN110025717B (zh) * | 2019-05-20 | 2022-02-08 | 上海中医药大学 | 知母皂苷酶解转化物在制备抑制皮肤浅表真菌药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20070023425A (ko) | 2007-02-28 |
KR101235115B1 (ko) | 2013-02-20 |
WO2007024108A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107441078B (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
CN106074971B (zh) | 一种降血糖中药组合物及制备方法与应用 | |
CN101033245B (zh) | 具栖冬青苷的制备方法及应用 | |
CN101396445A (zh) | 黄连总碱在制备糖尿病并发症治疗药物中的应用 | |
CN104840777B (zh) | 一种治疗糖尿病的中药制剂及其制备方法 | |
KR101235114B1 (ko) | 티모사포닌 a―ⅲ가 함유된 조성물의 용도 및 이의제조방법 | |
CN103494997B (zh) | 一种治疗高血糖和糖尿病的槐花中药物 | |
KR20160132134A (ko) | 당 대사 개선제 및 당 대사 개선 조성물 | |
CN101099753A (zh) | 救必应总皂苷的制备方法及应用 | |
CN104352624B (zh) | 蒙药芯芭正丁醇提取物在制备防治糖尿病药物中的应用 | |
CN105725187A (zh) | 一种降血糖组合物及其用于制备食品和保健食品的用途 | |
JP6735224B2 (ja) | アストロサイトのグルコース代謝活性化剤 | |
CN106938011A (zh) | 一种具有降血糖作用的中药及制备方法 | |
CN102716135B (zh) | 羽扇豆酮在制备预防或治疗糖尿病的产品中的应用 | |
CN101180065A (zh) | 用于预防和治疗2型糖尿病的包含知母皂苷a-ⅲ的组合物 | |
CA3022247C (en) | Composition for treating diabetic disease | |
CN107551167B (zh) | 互花米草提取物在制备降血尿酸功能产品中的用途 | |
CN102579530A (zh) | 具有抗糖尿病作用的太白楤木总皂苷的制备方法及药物 | |
CN104127816B (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
CN101099754A (zh) | 具栖冬青苷的制备方法及应用 | |
KR20190003092A (ko) | 복합 한약재 추출물을 유효성분으로 포함하는 스트레스 및 우울증의 예방, 개선 또는 치료용 조성물 | |
JP2007520548A (ja) | 糖尿病性合併症の予防及び治療用組成物 | |
CN108403980B (zh) | 一种降血糖植物提取物有效部位及其制备方法和应用 | |
JPS6312445B2 (zh) | ||
CN110123827A (zh) | 一种治疗由代谢异常所致疾病的药物组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080514 |